Your search for bevacizumab returned 1 results

Axitinib demonstrated a significantly longer progression-free survival and higher objective response compared with sorafenib as second-line therapy for metastatic renal cell carcinoma, investigators Brian I. Rini, MD, of the Cleveland Clinic, and colleagues reported at the American Society of Clinical Oncology’s 2011 Annual Meeting.